Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 26, 2025 16:01 ET | Source: Immuneering Corporation

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a...
September 16, 2025 07:00 ET | Source: Immuneering Corporation

Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

Immuneering Appoints Dr. Thomas Schall as Chairman of the Board
August 26, 2025 16:05 ET | Source: Immuneering Corporation

Immuneering Announces Closing of $25 Million Private Placement

Immuneering Announces Closing of $25 Million Private Placement
August 25, 2025 08:00 ET | Source: Immuneering Corporation

Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib

Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib
August 21, 2025 08:00 ET | Source: Immuneering Corporation

Immuneering Announces $25 Million Private Placement

Immuneering Announces $25 Million Private Placement
August 13, 2025 16:05 ET | Source: Immuneering Corporation

Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates

Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates
April 02, 2025 08:00 ET | Source: Immuneering Corporation

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference
March 20, 2025 16:05 ET | Source: Immuneering Corporation

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
March 20, 2025 07:00 ET | Source: Immuneering Corporation

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

IMMUNEERING NAMES DR. IGOR MATUSHANSKY AS CHIEF MEDICAL OFFICER
February 03, 2025 16:05 ET | Source: Immuneering Corporation

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference